1.
Leuk Lymphoma
; 61(2): 481-484, 2020 02.
Artículo
en Inglés
| MEDLINE
| ID: mdl-31547738
2.
Br J Haematol
; 136(1): 127-30, 2007 Jan.
Artículo
en Inglés
| MEDLINE
| ID: mdl-17222200
RESUMEN
A pilot trial was initiated for chronic myeloid leukaemia patients, which employed imatinib for remission induction, followed by reduced-intensity conditioning and an in vivo T-cell depleted graft. Out of nine patients, six experienced a molecular relapse and one patient had a haematological relapse at a median interval of 5 months after transplantation. Five relapsing patients achieved a 2nd molecular remission after treatment with either donor lymphocyte infusions (n = 4) or imatinib (n = 1). Two of nine patients died due to infectious complications. The probability of survival 2 years after transplant was 74% (95% CI 42-100%).